Navigation Links
Study Reaffirms Superiority of Trofile(TM) Assay
Date:12/19/2007

termines whether a patient is infected with a strain of HIV that uses either the CCR5 coreceptor, the CXCR4 coreceptor, or a combination of CCR5 and CXCR4 to enter cells. The use of CCR5, CXCR4 or both coreceptors defines the "tropism" of the virus strain. Trofile amplifies the envelope gene from a patient's HIV genome (from their blood sample) and then uses it to make HIV particles containing the patient's virus envelope protein. The resultant HIV particles are then used to infect cells that contain the CCR5 co-receptor or the CXCR4 co- receptor on the cell surface. Once the virus infects the cell, it undergoes a single round of replication. Virus replication results in the production of luciferase from a luciferase gene that is carried into the cell by the virus. The production of luciferase in either CCR5 cells, CXCR4 cells or both cell types defines the co-receptor tropism of the patient virus.

Trofile has been used to select patients in all phase II and phase III studies of CCR5 antagonists to date. Data from Pfizer's phase III trials of maraviroc indicate that patients identified as being CCR5 tropic by Trofile achieved a significant reduction in viral load when maraviroc was added to an optimized background therapy, while patients identified by Trofile as CXCR4 or dual/mixed (CXCR4/CCR5) achieved no significant reduction in viral load when treated with maraviroc plus an optimized background regimen.

About Monogram

Monogram is advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious infectious diseases and cancer. The Company's products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. The Company's technology is also being used by numerous biopharmaceutical companies to develop new and improved anti-viral therapeutics and vaccines as well as targeted cancer therapeutics. More information
'/>"/>

SOURCE Monogram Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Kline Study: Better Brushing Habits Boost European Oral Care Sales
4. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
5. NASA study will help stop stowaways to Mars
6. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
9. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
10. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
11. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 2014 Earlier this month, a ... partnership with the U.S. Air Force on the performance ... indicated that this type of fuel made from mustard ... be important to America’s Eco friendly future. In fact, ... mandate to become independent of foreign oil over the ...
(Date:8/28/2014)... 28, 2014 Whitehouse Laboratories is excited ... partnership with PTI Inspection Systems that will ... of the art leak testing method development and validation ... currently available. As part of this agreement, Whitehouse Labs ... Leak Detection Instrument developed and manufactured by PTI. ...
(Date:8/27/2014)... Aug. 27, 2014 Rhythm, a biopharmaceutical company ... deficiencies that result in metabolic disorders, announced today that ... with the U.S. Securities and Exchange Commission (SEC) relating ... its common stock. The number of shares to be ... not yet been determined. Citigroup and Cowen ...
(Date:8/27/2014)... Aug. 27, 2014   MSC , a healthcare ... today announced the appointment of Mary Beth Loesch ... 28 years of experience preparing companies for rapid growth ... Executive Vice President of Corporate Development and Healthcare. In ... business , as well as corporate strategy and marketing. ...
Breaking Biology Technology:Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 2Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 4Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 5Whitehouse Labs Renews Partnership with PTI Inspection Systems 2Whitehouse Labs Renews Partnership with PTI Inspection Systems 3Rhythm Files Registration Statement for Proposed Initial Public Offering 2MSC names Mary Beth Loesch President and CEO 2
... TIANJIN, China , May 13 /PRNewswire-Asia/ -- A ... of,Biotechnology and Medicine (TJAB) and Genzyme Corporation was held in the,Tianjin ... , , ... executives including Rao Zihe, President of TJAB and,President of Nankai University, ...
...  Fibrocell Science, Inc. (OTC Bulletin Board: FCSC), ... cell therapies for aesthetic, medical and scientific applications, announced ... of azficel-T, an autologous cell therapy currently under review ... the treatment of moderate to severe nasolabial fold wrinkles. ...
... 13 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE YMI, TSX:YM), today reported ... March 31, 2010 . , ... "During the third quarter, we completed the merging into YM of ... of two promising new drug candidates in drug classes that have been ...
Cached Biology Technology:Tianjin International Joint Academy of Biotechnology and Medicine, Genzyme Enter into Strategic Partnership 2Fibrocell Science, Inc. Initiates Histology Study of azficel-T 2Fibrocell Science, Inc. Initiates Histology Study of azficel-T 3YM BioSciences third quarter 2010 operational and financial results 2YM BioSciences third quarter 2010 operational and financial results 3YM BioSciences third quarter 2010 operational and financial results 4YM BioSciences third quarter 2010 operational and financial results 5YM BioSciences third quarter 2010 operational and financial results 6YM BioSciences third quarter 2010 operational and financial results 7YM BioSciences third quarter 2010 operational and financial results 8YM BioSciences third quarter 2010 operational and financial results 9YM BioSciences third quarter 2010 operational and financial results 10YM BioSciences third quarter 2010 operational and financial results 11YM BioSciences third quarter 2010 operational and financial results 12YM BioSciences third quarter 2010 operational and financial results 13
(Date:8/28/2014)... Bethesda, MD FASEB MARC (Maximizing Access to Research ... the American Society of Human Genetics from October 18 ... awards are meant to promote the entry of students, ... mainstream of the basic science community and to encourage ... of Human Genetics. This year MARC conferred 16 ...
(Date:8/28/2014)... support of peer groups and clinicians is critical ... to recent University of Georgia research. , A ... County area determined that role models for successful ... of infants. , "Mothers who received that support ... said study co-author Alex Anderson, an associate professor ...
(Date:8/28/2014)... MD FASEB MARC (Maximizing Access to Research ... for the American College of Sports Medicine,s Conference ... 2014 in Miami, Florida. These awards are ... doctorates and scientists from underrepresented groups into the ... encourage the participation of young scientists at the ...
Breaking Biology News(10 mins):Breastfeeding study shows need for effective peer counseling programs 2
... Much about autism is unknown, but researchers from the ... learn more about the neurodevelopmental disorder and its most ... researchers from across the world in San Diego this ... Research (IMFAR). Rochester researchers are presenting six abstracts ...
... Earlier this year, Boston University researchers and collaborators ... and found hundreds of natural gas leaks under ... Phillips, associate professor of geography and environment and ... Studies (CEES), and his research partners will present ...
... Boring!" asserts the introduction to a recent special issue ... On the contrary, the ways in which cells obtain ... of macromolecules are crucial for life. And the basics ... multicellular organisms. This gives special importance to a new ...
Cached Biology News:Rochester autism researchers present new findings at IMFAR 2Rochester autism researchers present new findings at IMFAR 3Rochester autism researchers present new findings at IMFAR 4BU researchers identify extensive methane leaks under streets of Boston 2
... Direct In Situ Apoptosis Detection ... situ by the direct TUNEL ... tagged with a directly labeled ... fluorescence staining for 40 samples ...
... Sequi-Gen GT and PowerPac 3000 system, 220-240 V, ... 38 x 50 cm vertical slab gel format. ... cell, which is capable of separating nucleic acids ... plate chamber (IPC) assembly (IPC and bonded inner ...
... with temperature probe, 100-120 and 220-240 V, supports ... and 400 W. The temperature probe is used ... degrees C during electrophoresis. Built-in infrared capability allows ... are provided. Dimensions are 27.5 x 34 x ...
... coil, Trans-Blot cell, provides temperature ... and extended electrophoretic transfer (blotting) ... cell. Use of the super ... an external water recirculator, which ...
Biology Products: